PF-Atlas › Clinical Trials › NCT07036029

NAL ER IPF Respiratory Function and Safety Study

NAL ER · Phase 1

Registry ID
NCT07036029
Phase
Phase 1
Status
Completed
Drug / intervention
NAL ER
Sponsor
Trevi Therapeutics
Start
2025-08-21
Enrollment
9
Locations
2

About this trial

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

View NCT07036029 on ClinicalTrials.gov →

Explore related

All NAL ER trialsAll IPF trials

Related trials

NAL ER — NCT05964335NAL ER — NCT04030026NAL ER — NCT07671911
Medical disclaimer. This page summarizes public trial data for NCT07036029 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.